VP2HF

Computer model derived indices for optimal patient-specific treatment selection and planning in Heart Failure

Coordinatore	KING'S COLLEGE LONDON    more  Organization address address: Capital House, Weston St 42 city: London postcode: SE1 3QD contact info Titolo: Mr. Nome: Paul Cognome: Labbett Email: send email Telefono: 442078184 Fax: 442078187
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	5˙033˙161 €
EC contributo	3˙562˙998 €
Programma	FP7-ICT Specific Programme "Cooperation": Information and communication technologies
Code Call	FP7-ICT-2013-10
Funding Scheme	CP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-10-01   -   2016-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	KING'S COLLEGE LONDON  Organization address address: Capital House, Weston St 42 city: London postcode: SE1 3QD contact info Titolo: Mr. Nome: Paul Cognome: Labbett Email: send email Telefono: 442078184 Fax: 442078187	UK (London)	coordinator	0.00
2	CENTRON DIAGNOSTICS LTD  Organization address address: BROMLEY LANE 1 CHISLEHURST BUSINESS city: CHISLEHURST KENT postcode: BR7 6LH contact info Titolo: Mr. Nome: Christopher Cognome: Lawson Email: send email Telefono: +44 7891160593	UK (CHISLEHURST KENT)	participant	0.00
3	CHU COTE DE NACRE - CAEN  Organization address address: AVENUE DE LA COTE DE NACRE city: CAEN CEDEX 5 postcode: 14033 contact info Titolo: Ms. Nome: Cathy Cognome: Gaillard Email: send email Telefono: +33 2 31 06 53 49	FR (CAEN CEDEX 5)	participant	0.00
4	INSTITUT NATIONAL DE RECHERCHE EN INFORMATIQUE ET EN AUTOMATIQUE  Organization address address: Domaine de Voluceau, Rocquencourt city: LE CHESNAY Cedex postcode: 78153 contact info Titolo: Mrs. Nome: Mireille Cognome: Moulin Email: send email Telefono: +33 172925962 Fax: +33 1 74 85 42 42	FR (LE CHESNAY Cedex)	participant	0.00
5	PHILIPS FRANCE  Organization address address: rue de Verdun city: SURESNES postcode: 92156 contact info Titolo: Mr. Nome: Pascal Cognome: Behier Email: send email Telefono: +33 147281230	FR (SURESNES)	participant	0.00
6	PHILIPS TECHNOLOGIE GMBH  Organization address address: LUEBECKERTORDAMM city: HAMBURG postcode: 20099 contact info Titolo: Mr. Nome: Patrick Cognome: Keur Email: send email Telefono: +31 40 5740361	DE (HAMBURG)	participant	0.00
7	SIMULA RESEARCH LABORATORY AS  Organization address address: MARTIN LINGES VEI city: SNAROYA postcode: 1367 contact info Titolo: Dr. Nome: Samuel Cognome: Wall Email: send email Telefono: +47 986 29 471	NO (SNAROYA)	participant	0.00
8	UNIVERSITAT POMPEU FABRA  Organization address address: PLACA DE LA MERCE 10-12 city: BARCELONA postcode: 8002 contact info Titolo: Mrs. Nome: Eva Cognome: Martin Email: send email Telefono: +34 93 542 2140 Fax: +34 93 542 1440	ES (BARCELONA)	participant	0.00
9	UNIVERSITE CATHOLIQUE DE LOUVAIN  Organization address address: Place De L'Universite city: LOUVAIN-LA-NEUVE postcode: 1348 contact info Titolo: Prof. Nome: Jean-Louis Cognome: Vanoverschelde Email: send email Telefono: +32 2 7642859 Fax: +32 27648980	BE (LOUVAIN-LA-NEUVE)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

Heart failure (HF) is one of the major health issues in Europe affecting 6 million patients and growing substantially because of the ageing population and improving survival following myocardial infarction. The poor short to medium term prognosis of these patients means that, treatments such as cardiac re-synchronisation therapy and mitral valve repair can have substantial impact. However, these therapies, are ineffective in up to 50% of the treated patients and involve significant morbidity and substantial cost. The primary aim of VP2HF is to bring together image and data processing tools with statistical and integrated biophysical models mainly developed in previous VPH projects, into a single clinical workflow to improve therapy selection and treatment optimisation in HF. The tools will be tested and validated in 200 patients (including 50 historical datasets) across 3 clinical sites, including a prospective clinical study in 50 patients in the last year of the project. The key innovations in VP2HF that make it likely that the project results will be commercially exploited and have major clinical impact are; 1) all tools to process images and signals, and obtain the statistical and biophysical models will be integrated into one clinical software platform that can be easily and intuitively used by clinicians and tried out in the prospective clinical study and 2) by utilising a decision tree stratification approach, only the appropriate parts of the tool chain, that will add maximum value to the predictions will be used in individual patients, so that the more resource intensive parts will be used when they will add real value. We expect that the study results of substantial improved efficacy of decision making over current guidelines, and an integrated package that is used as part of clinical workflow will ensure the industrial project partners, in particular Philips, will develop project outputs into dedicated products that will have significant clinical impact.